Details of the Drug

General Information of Drug (ID: DMO2JBC)

Drug Name

Methamphetamine hydrochloride

Synonyms

Methamphetamine HCL; Methamphetamine hydrochloride; Methamphetaminium chloride; Methylamphetamine hydrochloride; Methylisomyn; Norodin hydrochloride; Adipex; Chestox; Deofed; Des-O-E; Desepin; Desodex; Desoxo-5; Desoxyfed; Desoxyne; Destim; Dexoval; Dexstim; Dextim; Dosoxy; Doxyfed; Drinalfa; Efroxine; Eufodrinal; Gerovit; Hyphet; Isophen; Isophen (VAN); Obedrin-LA; Pervitin; Philopon; Soxysympamine; Syndrox; Tonedron; d-Methaphetamine hydrochloride; (+)-Methamphetamine hydrochloride; 51-57-0; S-(+)-Methamphetamine hydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Approved	[1]

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski):
0

Molecular Weight

185.69

Topological Polar Surface Area

Not Available

Rotatable Bond Count

3

Hydrogen Bond Donor Count

2

Hydrogen Bond Acceptor Count

1

Chemical Identifiers

Formula: C10H16ClN
IUPAC Name: (2S)-N-methyl-1-phenylpropan-2-amine;hydrochloride
Canonical SMILES: CC(CC1=CC=CC=C1)NC.Cl
InChI: TWXDDNPPQUTEOV-FVGYRXGTSA-N
InChIKey: 1S/C10H15N.ClH/c1-9(11-2)8-10-6-4-3-5-7-10;/h3-7,9,11H,8H2,1-2H3;1H/t9-;/m0./s1

Cross-matching ID

PubChem CID: 66124
ChEBI ID: CHEBI:35340
CAS Number: 51-57-0
INTEDE ID: DR1041

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Methamphetamine Hydrochloride was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2	Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 2001 Aug;11(6):477-87.
3	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
4	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
5	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
6	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
7	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
8	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
9	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
10	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
11	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
12	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.